Skip to content

Study · Case report or series · n = 10 · 2015

3 results

Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.

Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, Kuroshima S, Kawakami A, Asahina I

International journal of oral and maxillofacial surgery21 Aug 2015Cited by 35 (Europe PMC)

PMID26304604 (opens in a new tab)DOI10.1016/j.ijom.2015.07.018 (opens in a new tab)PepBankPUB-26304604
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    Among patients with jaw osteonecrosis who received teriparatide, two of 10 discontinued due to adverse events.

    In plain wordsTwo of 10 patients with jaw osteonecrosis stopped teriparatide due to adverse events.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableDiscontinuation due to adverse events
    Study

    n = 10

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Discontinuations due to adverse events
    2 patients
    of 10 patients treated

    Source sentences

    Summary
    Two of the 10 cases dropped out due to adverse events.
    1 context sentence
    Summary · context
    The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here.
  2. 02HumanCase report or seriesEfficacy outcome

    Among eight remaining patients with jaw osteonecrosis, seven improved clinically during teriparatide treatment, while one did not improve.

    In plain wordsAmong eight patients with jaw osteonecrosis, seven improved during teriparatide treatment, while one did not improve.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedJaw symptoms
    Study

    n = 8

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Patients with clinical improvement of jaw symptoms
    7 patients
    of 8 remaining patients
    Patients without improvement of symptoms
    1 patients
    of 8 remaining patients

    Source sentences

    Summary
    Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms.
    1 context sentence
    Summary · context
    The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here.
  3. 03HumanCase report or seriesEfficacy outcome

    During teriparatide treatment, seven of eight remaining patients with jaw osteonecrosis showed progression of sequestration.

    In plain wordsDuring teriparatide treatment, seven of eight patients showed progression of dead bone separation in the jaw.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseProgression of sequestration
    Study

    n = 8

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Patients with progression of sequestration
    7 patients
    of 8 remaining patients

    Source sentences

    Summary
    Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms.
    1 context sentence
    Summary · context
    The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06061354

Teriparatide on Maxillary Sinus Floor Osseointegration

Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024

Bone Regeneration

Trial pageClinicalTrials.govUpdated 30 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.